Point72 Asia Singapore Pte. Ltd. Boosts Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Point72 Asia Singapore Pte. Ltd. increased its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS) by 36.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,844 shares of the company’s stock after acquiring an additional 1,033 shares during the quarter. Point72 Asia Singapore Pte. Ltd.’s holdings in Keros Therapeutics were worth $223,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. KBC Group NV raised its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. bought a new position in Keros Therapeutics in the third quarter worth about $89,000. LMR Partners LLP purchased a new stake in Keros Therapeutics in the third quarter worth about $213,000. Finally, Victory Capital Management Inc. purchased a new position in shares of Keros Therapeutics during the 3rd quarter worth approximately $216,000. Institutional investors own 71.56% of the company’s stock.

Analyst Upgrades and Downgrades

KROS has been the subject of a number of research analyst reports. Jefferies Financial Group began coverage on Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating for the company. Scotiabank started coverage on Keros Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $77.00 price objective for the company. Bank of America reduced their target price on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Finally, Guggenheim started coverage on shares of Keros Therapeutics in a report on Monday, September 23rd. They issued a “buy” rating and a $96.00 price objective on the stock. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $88.89.

Keros Therapeutics Stock Up 9.8 %

NASDAQ:KROS opened at $62.28 on Wednesday. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -11.95 and a beta of 1.20. The company’s 50 day moving average price is $59.67 and its 200-day moving average price is $52.37. Keros Therapeutics, Inc. has a 52 week low of $27.31 and a 52 week high of $73.00.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same period last year, the firm posted ($1.33) earnings per share. As a group, sell-side analysts anticipate that Keros Therapeutics, Inc. will post -5.28 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.